On Mar. 8, 2023, Amphastar Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) had granted approval of its New Drug Application for naloxone hydrochloride nasal spray 4mg, which is delivered utilizing the Company’s proprietary nasal delivery device.

Naloxone hydrochloride nasal spray 4mg was indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression for adult and pediatric patients.